Evolus (EOLS) stock

Beauty injectables , market cap $497M

Injectable neurotoxins and gels for beauty

Market cap $497M

$7.16

-2.58%

As of Monday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#30of 92

Pharma

Checks firing

3of 14

Choppy

From 52-week high

-23.1%

Above the 200-day

EOLS's Quality Score fell 1 point on Fri, Oct 30, to 5. Made no higher high and higher low.

Follow EOLS's news. Pro members can get an alert when Evolus files news, and see its trials, share raises, and its CEO's filings.

Get an alert when EOLS files newsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

Next2028“Commercialization of Estyme ® in Canada, Australia, and New Zealand is expected in 2028…”Launch, if approved · SEC filing · Aug 4

Cash$45.2M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

Why is EOLS down?

Down 3% over three years while the S&P 500 rose 89%.

Its diluted share count rose 15.0%, and its biggest one-day fall came on a results day.

Sources: Price history, Oct 30, 2026; Annual reports, Dec 31, 2025

1 more reason, free with an account →The other side and the timeline, for Pro members.

Key facts on EOLS

Key facts on EOLS
Since its 2024 high	Down 58% while sales grew 19%
Latest filing	10-Q, Aug 5 Filed its quarterly report (10-Q) for the quarter to Jun 30, 2026

1 more reason behind EOLS's 5, free with an account →2 more reasons behind EOLS's 5, for Pro members.

EOLS in the news

ReportReports Wednesday, after the close. Every 3 months, a company tells everyone how much it sold and earned. It rose after 4 of its last 4 reports, +18.7% on average. Past reports ›

What's next

Wed Nov 11: Stifel Healthcare Conference 2026Investor conference · date confirmed.

1 more date ahead: the conference, for Pro members.

Cash$45.2M in cash. One of the last four quarters brought cash in while the others used it.On Jun 30

EOLS catalysts

Coming up

After its last 4 reports it closed +18.7% on average, higher 4 of 4 times.

4 past catalysts since 2021, with sizes and sources, for Pro members.Get in free →

What's next for EOLS, and how long its cash lasts

Next step the company has named

2028“Commercialization of Estyme ® in Canada, Australia, and New Zealand is expected in 2028, subject to applicable regulatory approvals and review processes.”Launch, if approved · SEC filing · Aug 4

What it means: when the company plans to start selling, if the drug is approved.

For Pro members: 28 filings.

Cash runway Jun 30 balance sheet

$45.2M in cash

One of the last four quarters brought cash in while the others used it, so an average says little about the next.

What it means: a runway is counted only when each of the last four quarters used cash.

For Pro members: the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3, filed Jun 5, 2026)
At-the-market share sales program (S-3, filed Jun 5, 2026)

For Pro members: 1 raise and its amount, and the share count against a year ago.

Insiders

CEO David Moatazedi sold 105,108 shares on Sep 2. 4 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when David Moatazedi buys or sells

For Pro members: every trade, and David Moatazedi’s 18 filings and quotes.

Get an alert when EOLS files newsSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 20 daysFDA decisionIn 20 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $385MDeramiocelFDA decision due (PDUFA)
In 20 daysFDA decisionIn 20 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $1.0BMolgramostimFDA decision due (PDUFA)
In 50 daysFDA decisionIn 50 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.9BLorundrostatFDA decision due (PDUFA)

11 more FDA dates and 102 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 143 dates, ranked →

Why EOLS scores 5

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+1Long-term trend above a rising 200-⁠day average, down over two years

Run-up adds
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Size, Profit, Dilution, Volatility, Persistence, News, and Insider trades.

What every line is worth, and the reason behind it, on EOLS and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 8:06 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-⁠scored stocks returned 2.2x the average stock over the next month. How we tested it

Alert me when EOLS's Quality Score turns up

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Here is what Pro members see.

The same page for Pro members, on AMD
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on EOLS and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

EOLS has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on EOLS, and all 14 on every stock.Get in free →

EOLS RSI today: 42.8, below its 50-day, above its 200-day

Not scored

Not in the Quality Score: over 20 years of tests, 2006 to 2026, they added no edge.

RSI 1442.8
Above 30, below 50.
MACD (12, 26, 9)Above signal
Crossed above its signal line 3 sessions ago.
50-day average$7.95
The price is 9.9% below it.
200-day average$6.27
The price is 14.2% above it.
50/200 crossGolden cross
The 50-day crossed above the 200-day on Jun 18.
ADX 1415.7
Under 25, with +DI below -DI.
Support$6.91
Swing low from Oct 2, 3.5% below the price.
Resistance$7.24
Swing high from Jul 8, 1.0% above the price.
52-week high$9.31
From Sep 4, 30.0% above the price.
52-week low$3.86
From Mar 30, 46.1% below the price.
Chart patternNone
No triangle, channel, or wedge in the last year.
Bollinger Bands (20, 2)Inside
The bands run from $6.98 to $7.87.
Volume1.0x
Against its 20-day average, for the time of day.

The deep dive on EOLS

What it does and how it makes money3 findingsFor Pro members3 findings on what EOLS does and how it makes money, for Pro members
Where it stands2 findingsFor Pro members2 findings on where EOLS stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findings"As disclosed in Part I, Item 3 'Legal Proceedings,' we and certain of our officers were previously named as defendants in a securities class action lawsuit and we are a nominal defendant in derivative lawsuits filed against certain of our officers and directors." (10-K for fiscal 2025)SEC filing · Mar 3, 2026A new heading in its "Risk Factors" this year: "Our business is subject to trade policy risks, including tariffs and regulatory actions on imports which may have a material adverse impact on our results of operations and financial condition." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Mar 3, 2026, against the one of Mar 4, 2025
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades EOLS, for Pro members

10 more findings on EOLS, each with its source, for Pro membersGet in free →

How EOLS ranks in Pharma

EOLS is #30 of 92 by Quality Score.

How EOLS ranks in Pharma
1	ABBVAbbVie	6/14	21
2	LLYEli Lilly	6/14	20
3	GMABGenmab	5/14	18
	CYTKCytokinetics		Open for its score
	ELANElanco Animal Health		Open for its score
	EQEquillium		Open for its score
	ERASErasca		Open for its score
30	EOLSEvolus	3/14	5

When does EOLS report earnings, and what happens after?

Reports Wed Nov 4, after the close (in 2 days). Confirmed.

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What EOLS reported on Aug 5, 2026

The quarter

The figures are not read from the release yet.

The filing on EDGAR

Where the sales came from

EOLS's results filing gives no sales by line in a table we read.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Total net revenues	$330M to $337Mraised

Figures as filed (SEC filing, Aug 5)

4 more outlook lines, for Pro members.

The numbers

Market value: $497M; today
Sales: $316M; up 13.9% on the year
Free cash flow: -$18.3M; last 12 months

Sales grew 39% a year over 5 years, fiscal 2020 to 2025.

Its share count grew 4.8% a year over 3 years.

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on EOLS: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.Get in free →

+35.4%+14.2%+19.9%

Mar 3May 4Aug 5

Reported	When	Gap	Reaction	5 sessions
Aug 5, 2026After close	After close	+13.1%	+19.9%	+31.4%
May 4, 2026After close	After close	-2.3%	+14.2%	+13.3%
Mar 3, 2026After close	After close	+30.0%	+35.4%	+27.9%

EOLS closed higher after 4 of its last 4 reports.

All 4 reports, and EOLS's Quality Score going into each

Everyone reporting earnings this week

EOLS sales and profit by year

Sales and profit by year

Sales grew every year from 2018 to 2025, to $297M. It lost money in each of the eight years.

EOLS share count over time

Shares: 2.2% more than a year ago (to Jun 30).

Shares of EOLS outstanding, as filed
Shares outstanding	As of
66.1M	Jul 31, 2026
65.9M	Apr 30, 2026
65.1M	Feb 27, 2026
64.8M	Oct 31, 2025

Offerings, shelves, and splits of EOLS, from its filings
From its filings	Filed
Registered shares for a later sale (S-3)	Jun 5, 2026
Raised $50M in a sale of shares, about 10% of its market value	Mar 11, 2024

Insiders trading EOLS

EOLS insider trades

One insider sold $950K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest:

SellDavid Moatazedi$950KInsiderat $9.04 on Sep 2, filed Sep 4

SellDavid MoatazediInsider$950Kat $9.04 on Sep 2, filed Sep 4

EOLS's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Tatjana MitchellChief Financial Officer
David MoatazediOfficer · 4 trades
Rui AvelarOfficer · 3 trades
Albert G. White IIIDirector
Brady StewartDirector
David N. GillDirector
Karah Herdman ParschauerDirector
Vikram MalikDirector

See insider trades by person

Which ETFs hold EOLS?

In ETFs: EOLS is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Evolus

Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.

353 employeesNewport Beach, CAevolus.com

EOLS's score card

Evolus (EOLS): Quality Score 5, Below Average, #30 of 92 in Pharma, with its price, on Breakaway — The picture a link to this page shows when it is shared.

Pro members see every line of every stock's score.

What would turn EOLS's score around: 7 things
3 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawaySep 4David Moatazedi sold EOLS$950K at $9.04, filed Sep 4

Alerts are optional.

See EOLS's 14 chart checks

See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.

Straight Answers

As of Nov 2, 2026: EOLS's Quality Score is 5 (Below Average), #30 of 92 in Pharma. Insiders sold $950K in the last 6 months (Form 4).

Is EOLS a good stock to buy? What its Quality Score says

EOLS scores 5 today, which Breakaway calls Below Average. It is #30 of 92 in Pharma by Quality Score, with 3 of 14 chart checks firing. Down 3% over three years while the S&P 500 rose 89%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is EOLS's Quality Score?

EOLS scores 5 today, which Breakaway calls Below Average (0 to 5). That is #30 of 92 in Pharma by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind EOLS's 5.

Are insiders buying EOLS?

One insider sold $950K across 1 filing in the last 6 months. No open-⁠market buys on record. The newest is David Moatazedi, Insider, who sold $950K on Sep 2.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.